Rohto-mentholatum (vietnam) Co., Ltd.: FDA regulatory profile

Rohto-mentholatum (vietnam) Co., Ltd. appears in 8 indexed U.S. FDA records: 8 recall records, naming 7 distinct products. Latest dated event: a recall record dated 2026-07-29. Observations run 2026-07-29 to 2026-07-29, 8 dated records across 1 calendar year, busiest 2026 with 8. Recalls: 8 Class II (100%); 8 ongoing by lifecycle status, reported 2026-07-29; 8 with an FDA recall number, 8 with an initiation date, across 1 state, grouped into 1 FDA recall event. Every figure here is a count or a date computed from the indexed FDA datasets over a finite window: coverage-limited activity signals, never quality ratings or judgements about the firm. Recall records: Rohto Cooling Eye Drops ALL-IN-ONE (hypromellose 0.2% (D-0715-2026, Class II, 2026-07-29), Rohto Cooling Eye Drops Max Strength (naphazoline hydrochlor (D-0716-2026, Class II, 2026-07-29), Rohto Cooling Eye Drops Max Strength (naphazoline hydrochlor (D-0717-2026, Class II, 2026-07-29) and Rohto Cooling Eye Drops Optic Glow (naphazoline hydrochlorid (D-0718-2026, Class II, 2026-07-29). Recalling-firm addresses are recorded in N/A.

Regulatory snapshot

Indexed records 8
Recall records 8
Shortage entries 0
Source rows filed 0
Approval records 0
Current shortages 0
Resolved shortages 0
Discontinued shortages 0
Unique products 7
Recall classifications Class II: 8
Recall statuses Ongoing: 8
First observed 2026-07-29
Latest observed 2026-07-29
Latest event type recall
Dated observations 8
Years covered 1
Span (days) 0
Busiest year 2026 (8 records)
Recall states 1
With recall number 8 of 8
FDA recall events 1
Related firms / shortages 0 / 0

Counts, not a rating. Coverage-limited activity signals over the ingested window — never reputational scores or judgements about the firm or its products.

Record breakdown

DimensionValueRecordsShare
Recall classificationClass II8100%
Recall statusOngoing8100%

Recall history (8)

Every enforcement report attributed to this firm, newest first. Classification is the FDA's severity tier, status its lifecycle position — neither is a safety statement.

Product (as published)Recall numberClassificationStatusReportedInitiated
Rohto Cooling Eye Drops ALL-IN-ONE (hypromellose 0.2%, tetrahydrozoline HCL 0.05%, zinc su D-0715-2026 Class II Ongoing 2026-07-29 2026-07-14
Rohto Cooling Eye Drops Max Strength (naphazoline hydrochloride 0.03%, polysorbate 90, 0.2 D-0716-2026 Class II Ongoing 2026-07-29 2026-07-14
Rohto Cooling Eye Drops Max Strength (naphazoline hydrochloride 0.03%, polysorbate 80 0.2% D-0717-2026 Class II Ongoing 2026-07-29 2026-07-14
Rohto Cooling Eye Drops Optic Glow (naphazoline hydrochloride 0.03%, povidone 0.5%, propyl D-0718-2026 Class II Ongoing 2026-07-29 2026-07-14
Rohto Cooling Eye Drops Digi Eye (hypromellose 0.35%, tetrahydrozoline HCl 0.05%), Sterile D-0719-2026 Class II Ongoing 2026-07-29 2026-07-14
Rohto Cooling Eye Drops Dry Aid (povidone 0.68%, propylene glycol 0.3%), Sterile, 0.34 FL D-0720-2026 Class II Ongoing 2026-07-29 2026-07-14
Rohto Cooling Eye Drops Dry Aid (povidone 0.68%, propylene glycol 0.3%), Sterile, TWIN PAC D-0721-2026 Class II Ongoing 2026-07-29 2026-07-14
Rohto Cooling Eye Drops Cool Relief (naphazoline hydrochloride 0.012%, polysorbate 80 0.2% D-0722-2026 Class II Ongoing 2026-07-29 2026-07-14

Browse the wider classification index: Class II recalls.

Products and drugs named (7)

De-duplicated by record entity, not raw source row.

Source limitations

Built from the 8 ingested FDA records for this firm (8 recall, 0 shortage, 0 approval) — not its full regulatory history. The window is finite and can lag the live record, and alternate spellings of a firm name may sit under separate profiles. Confirm details at the linked official source. Regulatory information only: no safety assessment, no recommendation.

Where to go next

Source & provenance

Official source
https://open.fda.gov/apis/drug/enforcement/
Source dataset
openFDA (enforcement + shortages + Drugs@FDA)
Publication date
Not available
Ingested
2026-08-22

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.